Chimerix Inc. (NASDAQ:CMRX)’s share price dropped 2.9% during trading on Thursday . The stock traded as low as $4.64 and last traded at $4.64, with a volume of 229,189 shares changing hands. The stock had previously closed at $4.78.

CMRX has been the topic of several research analyst reports. FBR & Co reissued a “hold” rating on shares of Chimerix in a research note on Tuesday, May 10th. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research note on Wednesday, May 11th. JPMorgan Chase & Co. reissued a “hold” rating and set a $7.00 target price on shares of Chimerix in a research note on Tuesday, August 9th. Finally, Piper Jaffray Cos. set a $12.00 target price on shares of Chimerix and gave the company a “buy” rating in a research note on Thursday, August 18th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Chimerix presently has an average rating of “Hold” and a consensus target price of $15.72.

The stock has a 50-day moving average of $4.19 and a 200 day moving average of $4.90. The firm’s market cap is $207.50 million.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.12. The firm earned $1.80 million during the quarter, compared to analyst estimates of $1.98 million. Equities analysts expect that Chimerix Inc. will post ($1.78) earnings per share for the current fiscal year.

In other news, Director Ernest Mario bought 50,000 shares of Chimerix stock in a transaction dated Friday, June 24th. The shares were bought at an average price of $3.70 per share, for a total transaction of $185,000.00. Following the purchase, the director now owns 381,440 shares of the company’s stock, valued at $1,411,328. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO M Michelle Berrey bought 13,188 shares of Chimerix stock in a transaction dated Friday, June 24th. The stock was purchased at an average price of $3.69 per share, for a total transaction of $48,663.72. Following the purchase, the chief executive officer now directly owns 258,821 shares in the company, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

Other large investors have recently modified their holdings of the company. Trexquant Investment LP increased its stake in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 107,484 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Chimerix by 5.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 141,181 shares of the biopharmaceutical company’s stock valued at $1,264,000 after buying an additional 6,847 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock valued at $11,400,000 after buying an additional 515,029 shares in the last quarter.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.